Wellness That Matters: Black Health News & Community Care
- HHS cancelled $500 million in mRNA vaccine research funding, jeopardizing preparedness for future pandemics.
- Experts warn the move will stifle innovation, deter investment, and set the U.S. behind other nations in biomedical research.
- Public health leaders call the cuts a national security risk, reducing deterrence against biological threats and harming cancer research prospects.
(The Hill) – Health Secretary Robert F. Kennedy Jr.’s decision this week to cancel hundreds of millions of dollars in mRNA vaccine funding will leave the United States unprepared for the next pandemic and other public health emergencies, public health experts warned.
“I’ve tried to be objective & non-alarmist in response to current HHS actions—but quite frankly this move is going to cost lives,” President Trump’s former surgeon general Jerome Adams said in a post to X.
“mRNA technology has uses that go far beyond vaccines… and the vaccine they helped develop in record time is credited with saving millions.”
The first COVID-19 mRNA vaccines from Pfizer and Moderna hit the market in 2021, just a year after the virus first appeared. Vaccines typically take years to develop, but the mRNA shots were developed in record time due to a massive influx of funding from the first Trump administration, dubbed Operation Warp Speed.
The COVID shots proved safe and effective, and helped bring about an end to the pandemic. Experts say mRNA technology has the potential to revolutionize treatments for evolving pathogens, especially bird flu, because the platform can be easily modified.
On Tuesday, Kennedy cancelled $500 million worth of contracts related to mRNA vaccine research being funded by the Biomedical Advanced Research and Development Authority.
Instead, he said the agency will focus on platforms with “stronger safety records.”
Public health experts point out that reviews of the hundreds of millions, if not billions, of doses of mRNA shots administered worldwide have found very few adverse events.
“It’s pretty clear that the administration, or at least the secretary, has a political vendetta not just against vaccines but against mRNA in general,” said Jeff Coller, a professor of RNA biology and therapeutics at Johns Hopkins University.
Coller said the move will put the U.S. behind other nations in biomedical research and sends a “clear message” to scientists and the industry that it is not wise to invest in mRNA technology because if they do, they will likely not receive funding or approval from the federal government.
Jennifer Nuzzo, a professor of epidemiology and director of the Pandemic Center at Brown University School of Public Health, told The Hill that the cancellation is a threat to national security, as it opens the U.S. to future public health emergencies caused by biological warfare.
“One of the ways that we deter that from happening is to say the United States is absolutely committed to preparedness,” Nuzzo said. “When we take them off the table and leave nothing in their place, we basically signal to our adversaries that we are no longer interested in defending ourselves.”
In the long run, Nuzzo said, winding down research efforts on mRNA vaccine platforms will stifle medical innovation coming out of the U.S., including new treatments for diseases like cancer.
“It’s troubling on a number of fronts,” she said.
MRNA vaccines work by sending instructions to cells to make a specific type of protein found on the outer membrane of a virus. The body’s immune system is then able to recognize that protein as something foreign and will create antibodies to fight it.
That same general approach could be used to help potentially vaccinate someone against a particular cancer, according to Nuzzo.
“Cancers have a genetic signature,” she said. “We don’t know what’s going to happen but there are some preliminary studies that suggest it could be a very promising way to treat cancers.”
None of the canceled contracts directly deal with cancer research, but the move will likely cause a chilling effect among researchers that ultimately impacts cancer-related work, said Michael Osterholm, founding director of the Center for Infectious Disease Research and Policy and member of the Vaccine Integrity Project.
“I think you’re going to see anyone who is willing to invest in mRNA technology, pulling back, if not completely, getting out of this business,” he said.
“This is terribly unfortunate, given that we have a number of other infectious diseases for which this vaccine platform was being explored in terms of taking on other infectious diseases and including some cancer vaccines.”
Kennedy is deeply skeptical of vaccines in general, and mRNA vaccines in particular.
In 2021, he falsely said the mRNA COVID-19 vaccine was the “deadliest vaccine ever made.” Kennedy has also been facing pressure from fellow anti-vaccine activists for not doing enough to keep mRNA vaccines off the market.
He was criticized earlier this year when the Food and Drug Administration approved Moderna’s updated COVID-19 vaccine, even though the agency limited its use in children.
In a video posted to X on Tuesday, Kennedy falsely claimed mRNA shots don’t protect against respiratory viruses and don’t work if a virus mutates.
“One mutation and the vaccine becomes ineffective,” Kennedy said.
Following the announcement, public health experts urged Congress to restore funding towards mRNA vaccine research, with some calling it an “assault” on federal vaccine policy.
“The HHS Secretary continues a mindless assault on sound federal vaccine policy,” said Robert Steinbrook, director of the Public Citizen Health Reseach Group.
“The mRNA vaccine platform was essential to rapid vaccine development and deployment during the COVIVD-19 pandemic and remains essential to preparing for future public health emergencies.”
But the full extent of Kennedy’s move isn’t known.
A Moderna spokesperson told The Hill that they were not aware of any new award cancellations since their contract to help develop an H5N1 bird flu vaccine was canceled in May.
Gritstone Bio, another company on the HHS list of cancelled contracts, ceased operations earlier this year after the company filed for bankruptcy in 2024.
A spokesperson for Tiba Bio said HHS’s decision to terminate their BARDA contract “comes as a surprise” since its contract was for a therapeutic, not a vaccine, and it does not use mRNA technology. Instead, it uses a method called RNA interference, which the FDA approved to treat some diseases in 2018.
Read the full article on the original site
